Evidence map›Paper›PMID 29568517›Full record

ArticleTranslational neurodegeneration2018

Surfen and oxalyl surfen decrease tau hyperphosphorylation and mitigate neuron deficits in vivo in a zebrafish model of tauopathy.

Seyedeh Maryam Alavi Naini, Constantin Yanicostas, Rahma Hassan-Abdi, Sébastien Blondeel, Mohamed Bennis, Ryan J Weiss, Yitzhak Tor, Jeffrey D Esko, Nadia Soussi-Yanicostas

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Translational neurodegeneration, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Tau Isoforms: Gaining Insight intoInternational journal of molecular sciences · 2022
    Review
  3. Review
  4. Review
  5. Review
  6. Non-Rodent Genetic Animal Models for Studying Tauopathy: Review ofInternational journal of molecular sciences · 2021
    Review
  7. Zebrafish Models to Study New Pathways in Tauopathies.International journal of molecular sciences · 2021
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Seyedeh Maryam Alavi NainiPROTECT, Inserm, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Constantin YanicostasPROTECT, Inserm, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Rahma Hassan-AbdiPROTECT, Inserm, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Sébastien BlondeelPROTECT, Inserm, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Mohamed BennisCadi Ayyad University, Marrakesh, Morocco.
Ryan J WeissDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA.
Yitzhak TorDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA.
Jeffrey D EskoDepartment of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA, USA.
Nadia Soussi-YanicostasPROTECT, Inserm, Université Paris Diderot, Sorbonne Paris Cité, Paris, France. nadia.soussi@inserm.fr.ORCID http://orcid.org/0000-0001-7734-9401
Inserm · FRUniversity of California San Diego · USCadi Ayyad University · MACentre National de la Recherche Scientifique · FR

Funding

Glycoside Inhibitors of Tumor MetastasisR01CA112278 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ESKO, JEFFREY D · 2005 to 2009
$1.5M
NCI NIH HHS R01 CA112278
6 · The paper itself

Abstract

Background: Tauopathies comprise a family of neurodegenerative disorders including Alzheimer's disease for which there is an urgent and unmet need for disease-modifying treatments. Tauopathies are characterized by pathological tau hyperphosphorylation, which has been shown to correlate tightly with disease progression and memory loss in patients suffering from Alzheimer's disease. We recently demonstrated an essential requirement for 3- Results: In vivo treatment of Tg[HuC::hTau Conclusion: Our findings demonstrate for the first time that surfen, a well-tolerated molecule in clinical settings, and its derivative, oxalyl surfen, could mitigate or delay neuronal defects in tauopathies, including Alzheimer's disease.

Indexed as

Alzheimer’s diseaseHeparan sulfateOxalyl surfenSurfenTau hyperphosphorylationTauopathyTau proteinZebrafish

Identifiers

PMID29568517
PMCPMC5855975
OpenAlexW2792707447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.